* SpringWorks Therapeutics Inc SWTX.OQ reported a
quarterly
adjusted loss of 54 cents per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of $-1.25. The mean expectation of seven analysts
for the quarter was for a loss of $1.11 per share. Wall Street
expected results to range from $-1.32 to -99 cents per share.
* Revenue was $59.73 million; analysts expected $34.34
million.
* SpringWorks Therapeutics Inc's reported EPS for the
quarter was
a loss of 54 cents.
* The company reported a quarterly loss of $39.92 million.
* SpringWorks Therapeutics Inc shares had fallen by 11.8%
this
quarter and lost 9.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 0.3%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for SpringWorks
Therapeutics Inc is $63.13
This summary was machine generated from LSEG data August 7 at
01:32 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -1.11 -0.54 Beat
Mar. 31 2024 -1.17 -1.18 Missed
Dec. 31 2023 -1.24 -1.45 Missed
Sep. 30 2023 -1.33 -1.27 Beat